Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-finding study of ALT001 in amyotrophic lateral sclerosis
CTR20263355Phase 2Active
- Sponsor
- Darwin Biotechnology
- Start
- Sep 2026
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing ALT001 with Placebo (2 arms). Primary endpoint: Change from baseline in ALSFRS-R total score at Week 24. Started Sep 2026; status: active.
02
Drugs
ALT001
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on CTR20263355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263355.